Healthcare

4 Min read

Published On 04 Dec 2019 05:44 AM

According to an announcement by an international biotechnology company in China, Clover Biopharmaceuticals, thriving to develop new biological therapies, the first-ever cancer patient suffering from malignant pleural effusions was admitted in Australia in a fully human TRAIL-Trimer fusion protein, the phase I of SCB-313 trial. Five clinical studies to evaluate SCB-13 and recruit patients from Australia and China.